The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: FTSE 100 Slides; Lloyds Tumbles After Results

Thu, 30th Jul 2020 08:46

(Alliance News) - A dovish tone from the US Federal Reserve was unable to lift the FTSE 100 index in early dealings in London on Thursday amid a deluge of earnings reports, with Lloyds Banking the worst blue-chip performer after swinging to an interim loss.

Focus now turns to second-quarter GDP readings due from Germany and the US later in the day.

The FTSE 100 index was down 50.23 points, or 0.8%, at 6,081.23 early Thursday. The mid-cap FTSE 250 index was down 92.49 points, or 0.5%, at 17,155.17 and the AIM All-Share index was down 0.4% at 892.40.

The Cboe UK 100 index was down 0.9% at 606.05. The Cboe 250 was down 0.5% at 14,567.35 and the Cboe Small Companies flat at 9,134.15.

In mainland Europe, the CAC 40 in Paris was down 0.5% while the DAX 30 in Frankfurt was down 1.1% early Thursday.

Stocks ended higher in the US in the wake of the Fed's cautious tone, but trade in Asia overnight was more downbeat.

In Asia on Thursday, the Japanese Nikkei 225 index closed down 0.3%. In China, the Shanghai Composite ended down 0.2% while the Hang Seng index in Hong Kong is down 0.7%.

Fed Chair Jerome Powell warned that the spiking number of new coronavirus cases in recent weeks was likely already starting to hinder the fragile economic recovery from the pandemic-induced recession.

"The path forward for the economy is extraordinarily uncertain," Powell told a press conference. US second-quarter GDP data, out on Thursday, would likely be the worst numbers posted in modern history, he noted.

Powell said there is "clearly a risk" that the virus resurgence is hurting economic growth and the labour market rebound, pointing to early data showing that the initially steady recovery in household spending was hitting headwinds.

At its latest meeting, the Fed kept its benchmark interest rate on hold at near-zero levels.

The bank said in its statement that it would increase its holdings of Treasury bills and mortgage-backed securities "at least at the current pace to sustain smooth market functioning".

The dollar dropped Wednesday evening after the Fed's update, but has since gained back some ground.

Sterling was quoted at USD1.2959 early Thursday, lower than USD1.2968 at the London equities close on Wednesday. Sterling had surged just above the USD1.30 mark after the Fed decision.

The euro traded at USD1.1754 early Thursday, down on USD1.1767 late Wednesday. Against the yen, the dollar was quoted at JPY105.07, flat versus JPY105.08.

Gold was quoted at USD1,949.89 an ounce early Thursday, lower than USD1,955.22 on Wednesday. Brent oil was trading at USD43.36 a barrel early Thursday, soft on USD43.42 late Wednesday.

At the bottom of the FTSE 100 was Lloyds Banking Group, tumbling 7.1%. The lender reported a pretax loss of GBP602 million for the half-year to June 30, swinging from a profit of GBP2.90 billion a year ago.

Net income was down 16% to GBP7.41 billion, with net interest income down 11%.

The bank took a GBP3.82 billion impairment in the half - including GBP2.4 billion in the second quarter - up from GBP579 a year ago, and said it expects its impairments for the full-year to be between GBP4.5 billion to GBP5.5 billion.

The impairments taken in the half reflected "a significant deterioration in forward looking economic outlook".

Looking to the remainder of the year, Lloyds said: "There have been early signs of recovery in the group's core markets, mainly in consumer spending and the housing market, but the outlook remains highly uncertain and the impact of lower rates and economic fragility will continue for at least the rest of the year."

Compass shares shed 2.0% after the contract caterer reporting a 44% slump in organic revenue for the third quarter, bringing its year-to-date slide to 14%.

The third-quarter decline was led by Europe, down 54%. North America was down 45% and Rest of World down 20%.

Compass's operating margin for the quarter was minus 6.3%.

"The pace at which our volumes will recover is still unclear, especially given a possible increase in local lockdowns. We are encouraged by the relative improvement in performance in June, as well as the early signs of an acceleration in first time outsourcing opportunities. In the meantime, we continue to work with our clients to help them reopen safely. We are proactively managing the business, reducing our costs, rebuilding our margins and investing to strengthen our competitive advantages," said Compass.

Shares in Royal Dutch Shell were little moved, with 'A' shares down 0.3% and 'B' shares down 0.4%, despite the oil major reporting a sizeable second quarter impairment.

Adjusted earnings - previously referred to as CCS earnings attributable to shareholders excluding identified items - slumped to just USD638 million in the second quarter from USD3.46 billion a year ago.

Including a USD16.8 billion impairment charge - taken "as a result of revised medium- and long-term price and refining margin outlook assumptions in response to the Covid-19 pandemic and macroeconomic conditions as well as energy market demand and supply fundamentals" - Shell posted a loss attributable to shareholders of USD18.13 billion versus income of USD3.00 billion a year ago.

AstraZeneca shares rose 2.3%. The pharmaceutical firm reported a 12% rise in total revenue in the first half of the year to USD12.63 billion, while core earnings per share rose 24% to USD2.01.

The FTSE 100 constituent said its 2020 full-year guidance was unchanged at high single-digit to low double-digit percentage growth in revenue and mid- to high-teens growth in core EPS.

Astra held its first interim dividend steady at USD0.90 per share.

The economic events calendar on Thursday has Germany GDP readings at 0900 BST, eurozone unemployment at 1000 BST and US GDP and jobless claims figures at 1330 BST.

The US GDP figure due later will be "ugly", said Lloyds Banking.

"While the forecast fall is very large, activity rebounded in late May and through June. The focus now is on whether growth is faltering in July. For that reason, today's weekly jobless claims will also draw considerable attention," said Lloyds.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.